Finland· FI-REL-REL64410

Ubeslo

A icosapent-ethyl product containing obicetrapib hemicalcium, registered in Finland by A. Menarini International Licensing S.A..

ATC C10AX22

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedUbesloATCC10AX22REGISTER NO.FI-REL-REL64410PACKS LISTED0CHECKEDSeptember 27, 2026

The record

At a glance

Fimea (Finland)
Active substance
Obicetrapib hemicalcium
Manufacturer
A. Menarini International Licensing S.A.
Country
Finland (FI)
ATC code
C10AX22
ATC class
Icosapent-Ethyl
Defined daily dose
4 g, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f407659d-566e-4d2d-b0f7-46371351d187
GET /v1/drugs/f407659d-566e-4d2d-b0f7-46371351d187?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": null,
  "form": "tabletti, kalvopäällysteinen",
  "route": "Suun kautta",
  "ddd_unit": null,
  "strength": "10 mg",
  "atc_label": "obisetrapibi",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/26/2055/001-006",
  "fimea_rel_id": "REL64410",
  "authorised_at": "2026-09-18"
}

See everything about icosapent-ethyl.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.